NCT06228092View on ClinicalTrials.gov

Neostigmine/Glyco-pyrrolate 50 Mikrogram/kg or Sugammadex 2 mg/kg for Reversal of Neuromuscular Blockade in Elderly Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 4, 2023

Primary Completion Date

May 4, 2025

Study Completion Date

May 4, 2025

Conditions
Neuromuscular Blockade, Residual
Interventions
DRUG

neostigmine/glycopyrrolate

Anesthesia personnel will administer the drug as a bolus over 5 seconds in an intravenous catheter upon conclusion of anaesthesia with a TOF within the range from TOF count of 2 to a TOF ratio \< 0.60

DRUG

Sugammadex

Anesthesia personnel will administer the drug as a bolus over 5 seconds in an intravenous catheter upon conclusion of anaesthesia with a TOF within the range from TOF count of 2 to a TOF ratio \< 0.60

Trial Locations (3)

2830

Department of anaesthesia, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen

Unknown

Bispebjerg Hospital, Copenhagen

Department of Pediatric and Obstetric Anaesthesia, Rigshospitalet, Copenhagen

All Listed Sponsors
lead

Matias Vested

OTHER

NCT06228092 - Neostigmine/Glyco-pyrrolate 50 Mikrogram/kg or Sugammadex 2 mg/kg for Reversal of Neuromuscular Blockade in Elderly Patients | Biotech Hunter | Biotech Hunter